Klow Blend

The name gives away the recipe: the K stands for KPV, the rest for the familiar Glow combination. Klow Blend extends the triple mixture of GHK-Cu, BPC-157 and TB-500 with a fourth peptide, the copper peptide still making up the largest share while the other three are present in smaller, equal amounts.

KPV is the tripeptide lysine-proline-valine, the C-terminal end of the hormone alpha-MSH. In models it inhibits pro-inflammatory transcription factors, NF-kB above all. The evidence is strongest in chronic inflammation of gut and skin, where the data are considered substantial.

The mixture thus serves four levels at once:

1. tissue repair and new vessel formation via BPC-157
2. cell migration and mobilisation of stem cells via TB-500
3. collagen formation and microcirculation via GHK-Cu
4. dampening of inflammatory signals via KPV

The fourth point is the actual reason for the extension. In models of chronic inflammation the repair cascade alone is often not enough, because persistent inflammatory signals keep undermining the rebuild. That is exactly where KPV comes in.

Organisationally, the advantage of any ready-made mixture remains: four peptides in one step, dissolve once, a fixed ratio. Over experimental series of several weeks that matters. The flip side: the four-way combination itself has barely been examined; the statements come from research on the individual peptides. If you look for evidence on the mixture as a whole, you will not find any.

All four ingredients show a mild profile in the preclinical literature, and on current knowledge this also holds for the combination. The four-way form is less well described than the separate peptides, however, and long-term human studies are missing throughout.

• Injection site: redness, a feeling of pressure or a brief irritation after subcutaneous administration, the most frequent observation.
• Copper share: GHK-Cu can slightly intensify local irritation at the injection site compared with copper-free solutions.
• New vessel growth via TB-500: a theoretical concern is debated that stimulated angiogenesis also supplies pre-existing abnormal tissue. There is no evidence for this.

This summary is no substitute for medical advice.

• Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing - critical review of the BPC-157 share: positive findings in tendon, ligament and muscle, almost only from rodent studies, human data open.
• Thymosin beta4 accelerates wound healing - rat wounds under thymosin β4: up to 61 % more epithelial closure than controls, plus more collagen and new vessels.
• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation - KPV enters gut and immune cells through the transporter PepT1, curbs NF-κB and MAP kinases there and eased inflammation in two mouse colitis models when given orally.
• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data - review of the GHK-Cu share: more collagen, elastin and glycosaminoglycans, sprouting of vessels and nerves, interpreted through gene expression data.